InspireMD AI Stock Analysis
Want to see NSPR full AI Analyst Report?
InspireMD (NSPR) AI Stock Analysis
InspireMD
(NASDAQ:NSPR)
Weak financial performance and poor valuation are the primary drags, while earnings-call catalysts and the positive warrant amendment provide meaningful offsets; technical indicators remain neutral.
InspireMD Key Performance Indicators (KPIs)
Revenue by GeographyBreaks down where the company earns sales across countries and regions, showing which markets drive current revenue. For a small medical-device firm like InspireMD, geographic concentration highlights dependence on a few markets, distributors, or regulatory approvals, while expansion into new regions points to commercial traction and growth potential. Also signals exposure to currency moves, local reimbursement and healthcare funding, and where future upside or downside is most likely to occur.
Revenue has been dominated by the 'Other' bucket and steady European markets, but two structural shifts stand out: first commercial revenue in the U.S. appears only in late‑2025—an important commercialization inflection if sustained—and Russia’s contribution disappears in 2025, removing a prior revenue source (and geopolitical risk). Italy and Poland show healthy regional expansion; monitor whether U.S. momentum can replace lost Russian sales and whether 'Other' is truly diversified or a concentration risk.
The FlyInspireMD (NSPR) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $36.26M
- Dividend Yield
- ―
- Average Volume (3M)
- 179.73K
- Price to Earnings (P/E)
- -1.6
- Beta (1Y)
- -0.42
- Revenue Growth
- 53.42%
- EPS Growth
- 22.08%
- Country
- US
- Employees
- 127
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
InspireMD Business Overview & Revenue Model
Company Description
InspireMD, Inc., an Israel-based medical technology company established in 2005, specializes in creating and commercializing advanced medical devices. Its core expertise lies in the proprietary MicroNet stent platform technology, engineered to addres...
InspireMD Earnings Call Summary
The call presented a mix of encouraging operational and regulatory progress (21% international revenue growth, constructive FDA interactions, multiple potential approvals, enrollment in a pivotal SwitchGuard study, and planned annualized cost savings of ~$9 million) alongside significant near‑term challenges (voluntary recall driving $734k in customer credits and a $612k inventory impairment, a swing to negative GAAP gross margin, a wider net loss of $14.3M, and a substantial cash decline from $54.2M to $30.4M). Management articulated a clear remediation and relaunch plan and emphasized underlying demand, but financial impacts and regulatory timing risk keep the outlook balanced between opportunity and near‑term execution/liquidity challenges.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management provided multi‑pronged guidance focused on regulatory and commercial milestones: potential FDA decisions in Q4 2026 for CGuard Prime 80 (TCAR) and the original CGuard CAS platform, targeted market re‑entry for the redesigned CGuard Prime 135 in H1 2027 (possible earlier approval), and a SwitchGuard pivotal program aiming toward a H2 2027 U.S. approval/launch; if approvals occur, the company expects to address roughly 75,000 annual U.S. stenting procedures and says Prime 80 would roughly double its addressable market. Financial and operational metrics/guidance included Q2 FY2026 results of total revenue $1.8M (international revenue $2.1M, +21% YoY), a Q2 gross loss of $0.8M (‑43.7% of revenue) driven by a $734k customer credit and $612k inventory impairment (adjusted non‑GAAP gross profit $0.6M), operating expenses $13.7M, net loss $14.3M (‑$0.17/share), cash & marketable securities $30.4M (6/30/26), a ~20% workforce reduction expected to save ~$9M annually with a Q3 restructuring charge of $0.9–1.2M, and most cost savings expected to be realized by Q4 2026.
InspireMD Financial Statement Overview
Summary
Revenue growth potential exists but is undermined by widening net losses, deeply negative operating and free cash flows, and recent TTM deterioration; low debt offers limited stability in a high-burn environment.
Income Statement
25NegativeBalance Sheet
45NeutralCash Flow
15Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 10.84M | 8.98M | 7.01M | 6.21M | 5.17M | 4.50M |
| Gross Profit | 1.96M | 2.65M | 1.51M | 1.81M | 1.12M | 754.00K |
| EBITDA | -37.86M | -48.25M | -31.67M | -19.62M | -18.27M | -14.55M |
| Net Income | -38.50M | -48.79M | -32.01M | -19.92M | -18.49M | -14.92M |
Balance Sheet | ||||||
| Total Assets | 44.64M | 69.40M | 46.81M | 47.64M | 24.65M | 39.71M |
| Cash, Cash Equivalents and Short-Term Investments | 30.42M | 54.21M | 34.64M | 39.02M | 17.80M | 34.04M |
| Total Debt | 1.97M | 3.29M | 2.34M | 1.59M | 1.61M | 1.20M |
| Total Liabilities | 13.13M | 14.20M | 10.72M | 8.14M | 7.26M | 6.18M |
| Stockholders Equity | 31.51M | 55.20M | 36.09M | 39.50M | 17.39M | 33.53M |
Cash Flow | ||||||
| Free Cash Flow | -42.46M | -36.77M | -23.27M | -16.76M | -16.02M | -13.55M |
| Operating Cash Flow | -41.21M | -35.10M | -21.87M | -16.38M | -15.54M | -13.21M |
| Investing Cash Flow | -8.15M | -30.56M | 12.64M | -16.09M | 8.44M | -22.46M |
| Financing Cash Flow | 52.93M | 55.57M | 18.45M | 37.53M | -140.00K | 35.03M |
InspireMD Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NSPR, the sentiment is Positive. The current price of 0.80 is above the 20-day moving average (MA) of 0.54, above the 50-day MA of 0.64, and below the 200-day MA of 1.04, indicating a neutral trend. The MACD of 0.03 indicates Negative momentum. The RSI at 66.37 is Neutral, neither overbought nor oversold. The STOCH value of 78.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NSPR.
InspireMD Risk Analysis
InspireMD disclosed 46 risk factors in its most recent earnings report. InspireMD reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksInspireMD Peers Comparison
Overall Rating
VANI58Neutral
ANIK56Neutral
APYX53Neutral- NSPR51Neutral
XTNT41Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| VANI | 58Neutral | $103.73M | -3.29 | -191.05% | ― | ― | 19.38% |
| ANIK | 56Neutral | $180.43M | -101.51 | -1.28% | ― | 9.42% | 94.37% |
| APYX | 53Neutral | $123.42M | -14.82 | -70.78% | ― | 24.35% | 46.90% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| NSPR | 51Neutral | $36.26M | -1.57 | -79.21% | ― | 53.42% | 22.08% |
| XTNT | 41Neutral | $38.57M | -3.34 | -23.45% | ― | -14.27% | -132.84% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| NSPR | InspireMD Inc | 0.80 | -1.07 | -57.22% | |
| ANIK | Anika Therapeutics, Inc. | 13.95 | 3.85 | 38.12% | |
| APYX | Apyx Medical | 3.00 | -1.07 | -26.29% | |
| VANI | Vivani Medical, Inc. | 1.13 | -0.23 | -16.61% | |
| XTNT | Xtant Medical Holdings Inc | 0.28 | -0.38 | -58.03% |
InspireMD Corporate Events
InspireMD Amends Warrants to Support CGuard Prime Launch
PositiveOn September 21, 2026, InspireMD amended certain Series J and Series K warrants originally issued in a May 2023 private placement, covering roughly 4.8 million Series J and 9.5 million Series K underlying shares held by participating investors, inclu...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 05, 2026